BR9814984A - Processos para tratar condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio em uma paciente pós-menopáusica e para reduzir o risco de fraturas ósseas osteoporóticas em uma paciente, e, conjunto para uso por uma comsumidora atormentada com, ou suscetìvel a, condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio - Google Patents

Processos para tratar condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio em uma paciente pós-menopáusica e para reduzir o risco de fraturas ósseas osteoporóticas em uma paciente, e, conjunto para uso por uma comsumidora atormentada com, ou suscetìvel a, condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio

Info

Publication number
BR9814984A
BR9814984A BR9814984-9A BR9814984A BR9814984A BR 9814984 A BR9814984 A BR 9814984A BR 9814984 A BR9814984 A BR 9814984A BR 9814984 A BR9814984 A BR 9814984A
Authority
BR
Brazil
Prior art keywords
postmenopausal
patient
physical conditions
resulting
processes
Prior art date
Application number
BR9814984-9A
Other languages
English (en)
Inventor
Steven Cummings
Herman Ellman
Bruce Ettinger
Original Assignee
Univ California
Kaiser Foundation Health Plan
Permanente Medical Group Inc
Berlex Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25523181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9814984(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Kaiser Foundation Health Plan, Permanente Medical Group Inc, Berlex Lab filed Critical Univ California
Publication of BR9814984A publication Critical patent/BR9814984A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PROCESSOS PARA TRATAR CONDIçõES FìSICAS RESULTANTES DO DECLìNIO PóS-MENOPáUSICO DE ESTROGêNIO EM UMA PACIENTE PóS-MENOPáUSICA E PARA REDUZIR O RISCO DE FRATURAS óSSEAS OSTEOPORóTICAS EM UMA PACIENTE, E, CONJUNTO PARA USO POR UMA CONSUMIDORA ATORMENTADA COM, OU SUSCETìVEL A, CONDIçõES FìSICAS RESULTANTES DO DECLìNIO PóS-MENOPáUSICO DE ESTROGêNIO" A presente invenção proporciona processos para tratar de condições físicas resultantes dodeclínio pós-menopáusico de estrogênio em uma paciente pós-menopáusica, e, em particular, processos para reduzir o risco de fraturas osteoporóticas dos ossos no dito período pós-menopáusico. A presente invenção também provê um conjunto útil para executar os processos da presente invenção.
BR9814984-9A 1997-11-21 1998-11-19 Processos para tratar condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio em uma paciente pós-menopáusica e para reduzir o risco de fraturas ósseas osteoporóticas em uma paciente, e, conjunto para uso por uma comsumidora atormentada com, ou suscetìvel a, condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio BR9814984A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/975,599 US5891868A (en) 1997-11-21 1997-11-21 Methods for treating postmenopausal women using ultra-low doses of estrogen
PCT/US1998/024677 WO1999026631A1 (en) 1997-11-21 1998-11-19 Methods for treating postmenopausal women using ultra-low doses of estrogen

Publications (1)

Publication Number Publication Date
BR9814984A true BR9814984A (pt) 2000-10-03

Family

ID=25523181

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814984-9A BR9814984A (pt) 1997-11-21 1998-11-19 Processos para tratar condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio em uma paciente pós-menopáusica e para reduzir o risco de fraturas ósseas osteoporóticas em uma paciente, e, conjunto para uso por uma comsumidora atormentada com, ou suscetìvel a, condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio

Country Status (26)

Country Link
US (1) US5891868A (pt)
EP (2) EP1570848B1 (pt)
JP (2) JP2001523722A (pt)
KR (1) KR100576568B1 (pt)
CN (1) CN100398110C (pt)
AT (2) ATE383862T1 (pt)
AU (1) AU760108B2 (pt)
BR (1) BR9814984A (pt)
CA (1) CA2306881C (pt)
CL (1) CL2004001852A1 (pt)
CZ (1) CZ299226B6 (pt)
DE (2) DE69829501T2 (pt)
EA (1) EA004573B1 (pt)
EE (1) EE04221B1 (pt)
ES (2) ES2299912T3 (pt)
HK (1) HK1082919A1 (pt)
HU (1) HUP0004339A3 (pt)
IL (1) IL136175A (pt)
IS (1) IS2132B (pt)
NO (1) NO326929B1 (pt)
NZ (1) NZ504668A (pt)
PL (1) PL193897B1 (pt)
PT (1) PT1032398E (pt)
SK (1) SK284971B6 (pt)
TR (1) TR200001460T2 (pt)
WO (1) WO1999026631A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
CA2396098A1 (en) * 2000-01-14 2001-07-19 Sterix Limited Pharmaceutical compositions containing steroidal structures and uses thereof
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
EP1334367B1 (en) * 2000-10-13 2006-06-07 Abbott Laboratories A method of determining the initial dose of vitamin d compounds
WO2003011282A1 (en) 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
WO2005011618A2 (en) * 2003-07-31 2005-02-10 Ivax Corporation Methods for the treatment of male and female sexual dysfunction
US7685012B2 (en) * 2003-12-30 2010-03-23 Wilson Thomas W Method and system for analyzing resource allocation based on cohort times
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
CA2601773A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US8217024B2 (en) * 2005-12-27 2012-07-10 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
US20070254036A1 (en) * 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
CN104398496B (zh) * 2007-10-15 2018-03-20 阿尔扎公司 芬太尼的一天更换一次透皮施用
US20090110656A1 (en) * 2007-10-31 2009-04-30 Lemke Sarah A Skin cooling composition
US20090157153A1 (en) * 2007-12-13 2009-06-18 Sarah Anne Lemke Skin cooling system
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
CN106038574A (zh) * 2010-04-15 2016-10-26 拜耳知识产权有限责任公司 用于hrt的低剂量的固体口服剂型
HUP1000335A2 (en) * 2010-06-22 2012-02-28 Avidin Kft Use of an estrogen derivative for the treatment and/or prevention of psychiatric conditions
RU2456955C1 (ru) * 2011-03-01 2012-07-27 Государственное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ ортопедического лечения женщин постменопаузального периода съемными пластиночными протезами
CN102397550B (zh) * 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
JP2013097693A (ja) * 2011-11-04 2013-05-20 Hitachi Solutions Ltd 骨粗鬆症リスク判定システム及びプログラム
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150098983A1 (en) * 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
SE8602666D0 (sv) * 1986-06-16 1986-06-16 Leo Ab Intravaginal devices
US5188835A (en) * 1986-06-16 1993-02-23 Kabi Pharmacia Ab Intravaginal devices
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen

Also Published As

Publication number Publication date
DE69839026T2 (de) 2009-01-08
EA004573B1 (ru) 2004-06-24
NO326929B1 (no) 2009-03-16
ES2299912T3 (es) 2008-06-01
CL2004001852A1 (es) 2005-06-03
JP2004083599A (ja) 2004-03-18
HUP0004339A2 (hu) 2001-05-28
CN1279611A (zh) 2001-01-10
NZ504668A (en) 2002-11-26
KR20010032257A (ko) 2001-04-16
AU760108B2 (en) 2003-05-08
NO20002587L (no) 2000-07-19
DE69839026D1 (de) 2008-03-06
EP1570848A1 (en) 2005-09-07
HK1082919A1 (en) 2006-06-23
IS2132B (is) 2006-08-15
AU1591499A (en) 1999-06-15
CA2306881C (en) 2008-09-02
PL341112A1 (en) 2001-03-26
TR200001460T2 (tr) 2000-11-21
EA200000563A1 (ru) 2001-08-27
EE04221B1 (et) 2004-02-16
JP2001523722A (ja) 2001-11-27
HUP0004339A3 (en) 2001-09-28
WO1999026631A1 (en) 1999-06-03
ATE291430T1 (de) 2005-04-15
EP1570848B1 (en) 2008-01-16
SK7332000A3 (en) 2001-03-12
PT1032398E (pt) 2005-08-31
SK284971B6 (sk) 2006-03-02
DE69829501D1 (de) 2005-04-28
EP1032398B1 (en) 2005-03-23
PL193897B1 (pl) 2007-03-30
IS5468A (is) 2000-04-26
DE69829501T2 (de) 2006-01-26
IL136175A (en) 2005-11-20
CZ20001602A3 (cs) 2001-02-14
NO20002587D0 (no) 2000-05-19
CZ299226B6 (cs) 2008-05-21
ES2241188T3 (es) 2005-10-16
US5891868A (en) 1999-04-06
ATE383862T1 (de) 2008-02-15
CA2306881A1 (en) 1999-06-03
CN100398110C (zh) 2008-07-02
EP1032398A1 (en) 2000-09-06
KR100576568B1 (ko) 2006-05-08
EE200000307A (et) 2001-10-15
IL136175A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
BR9814984A (pt) Processos para tratar condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio em uma paciente pós-menopáusica e para reduzir o risco de fraturas ósseas osteoporóticas em uma paciente, e, conjunto para uso por uma comsumidora atormentada com, ou suscetìvel a, condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio
DE59101613D1 (de) Knochennagel zur Versorgung von Oberarmfrakturen.
ATE127691T1 (de) Verwendung von vitamin-d-analoga zur behandlung von akne.
BR0212809A (pt) Inibidores de anticorpos de gdf-8 e usos dos mesmos
BR0315598A (pt) Anticorpos neutralizantes contra gdf-8 e usos dos mesmos
SE9500566L (sv) L-platta
DE693928T1 (de) Aminozucker- und glykosaminoglykanzusammensetzung zur behandlung und reparatus von bindegewebe
DE69726245D1 (de) Befeuchtungsgerät zur Behandlung von Atemstillstand im Schlaf
BR9906438A (pt) Composição de reforço nutricional apropriada para o tratamento de úlceras de pressão
DE69821793D1 (de) Neuronale verwendungen des bmp-11
DE69712578T2 (de) Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase
NO972426L (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
DE69331546T2 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
DE60118769D1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
BR9811643A (pt) Suplementação quìmica de osso
DE69503724D1 (de) L-Carnitin-Salz, dieses enthaltende kosmetische und pharmazeutische Zusammensetzungen zur Behandlung von Dermatosen
MY120530A (en) Combination preparation for use in dementia
ATE342059T1 (de) Verwendung zur verabreichung von östrogen
BR9811963A (pt) Uso de 17-alfa-estradiol para o tratamento de pele envelhecida ou danificada pelo sol e/ou atrofia de pele
ATA141495A (de) Schraubbefestigung zur fixation von knochenfrakturen od. dgl.
DE551180T1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE321528T1 (de) Verwendung von dattelkern-extrakt zur minderung der anzeichen der hautalterung
WO2001030811A3 (en) Complex comprising an igfiie polypeptide-fragment and an igfbp2 polypeptide and its use in the treatment of osteoporosis
DE69422215T2 (de) Chirurgisches Instrument zur Behandlung von Frakturen oder Pseudoarthrose des kahnförmigen Handwurzelknochens
WO2000037093A8 (fr) Inhibiteur de resorption osseuse

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: A61K 31/565, A61P 15/12

Ipc: A61K 31/565 (2007.10), A61P 15/12 (2007.10)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ARTIGOS 10, XIII, 8O E 11 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.